These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 4084735)

  • 21. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy.
    Lilleby W; Torlakovic G; Torlakovic E; Skovlund E; Fosså SD
    Cancer; 2001 Jul; 92(2):311-9. PubMed ID: 11466684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment outcomes with permanent brachytherapy in high-risk prostate cancer patients stratified into prognostic categories.
    Bittner N; Merrick GS; Galbreath RW; Butler WM; Adamovich E
    Brachytherapy; 2015; 14(6):766-72. PubMed ID: 26489923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Outcomes and predictors of T3a prostate cancer treated by permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy].
    Mai Z; Yan W; Li H; Zhou Y; Zhou Z; Chen J
    Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):765-70. PubMed ID: 25573217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic classification as an alternative to anatomic staging for clinically localized prostate cancer: a proposal based on patients treated with external beam radiotherapy.
    Ennis RD; Malyszko BK; Rescigno J; Whitman AE; Heitjan DF; O'Toole KM; Rubin M; Schiff PB
    Urology; 1998 Feb; 51(2):265-70. PubMed ID: 9495709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiotherapy in cT3 prostatic carcinoma: retrospective comparison between neoadjuvant and adjuvant hormonotherapy.
    Cellini N; Luzi S; Morganti AG; Valentini V; Mantini G; Racioppi M; Smaniotto D; Leone M; Mattiucci GC; Digesù C; Giustacchini M; Destito A; Alcini E
    Urol Int; 2004; 72(1):21-7. PubMed ID: 14730161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden.
    Andrén O; Fall K; Franzén L; Andersson SO; Johansson JE; Rubin MA
    J Urol; 2006 Apr; 175(4):1337-40. PubMed ID: 16515993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer.
    Petrovich Z; Lieskovsky G; Langholz B; Jozsef G; Streeter OE; Skinner DG
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):600-9. PubMed ID: 12062603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.
    Shipley WU; Thames HD; Sandler HM; Hanks GE; Zietman AL; Perez CA; Kuban DA; Hancock SL; Smith CD
    JAMA; 1999 May; 281(17):1598-604. PubMed ID: 10235152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of DNA content to conventional prognostic factors in clinically localised carcinoma of the prostate.
    Ritchie AW; Dorey F; Layfield LJ; Hannah J; Lovrekovich H; deKernion JB
    Br J Urol; 1988 Sep; 62(3):245-60. PubMed ID: 3191338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of external beam radiotherapy on prostatic carcinoma DNA content as measured by static image cytometry.
    O'Sullivan DC; Barrett DM; Colby TV; Lieber MM; Cupps RE
    Eur Urol; 1992; 21(3):235-9. PubMed ID: 1499632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of transurethral resection on prognosis in carcinoma of the prostate: real or imaginary?
    McGowan DG
    Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1057-64. PubMed ID: 3182338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of the local control in lymph-node staged localized prostate cancer treated by external beam radiotherapy, assessed by digital rectal examination, serum prostate-specific antigen and biopsy.
    Borghede G; Aldenborg F; Wurzinger E; Johansson KA; Hedelin H
    Br J Urol; 1997 Aug; 80(2):247-55. PubMed ID: 9284197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deferred treatment in clinically localised prostatic carcinoma.
    Adolfsson J; Carstensen J; Löwhagen T
    Br J Urol; 1992 Feb; 69(2):183-7. PubMed ID: 1537031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes.
    Leapman MS; Cowan JE; Simko J; Roberge G; Stohr BA; Carroll PR; Cooperberg MR
    Eur Urol; 2017 May; 71(5):750-759. PubMed ID: 27940155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate.
    Rosser CJ; Levy LB; Kuban DA; Chichakli R; Pollack A; Lee A; Pisters LL
    J Urol; 2003 Jun; 169(6):2160-5. PubMed ID: 12771739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.